Effect of alpha-methyl-para-tyrosine on response to cocaine challenge

Biological Psychiatry

Volumn 42, Issue 3, 1997, Pages 181-190

  Stine, Susan M ^a,b   Krystal, John H ^a,b   Petrakis, Ismene L ^a,b   Jatlow, Peter I ^a,c,d   Heninger, George R ^a,c   Kosten, Thomas R ^a,c   Charney, Dennis S ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c Yale University School of Medicine   (United States)

^d YALE NEW HAVEN HOSPITAL   (United States)

Author keywords

Abuse; Cocaine; Dependence; Dopamine AMPT; Pharmacotherapy

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; COCAINE; HOMOVANILLIC ACID; METIROSINE;

ARTICLE; BLOOD PRESSURE MEASUREMENT; CATECHOLAMINE RELEASE; DOSE RESPONSE; DRUG ABUSE; DRUG BLOOD LEVEL; FEMALE; HEART RATE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; NORMAL HUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; ALPHA-METHYLTYROSINE; AROUSAL; COCAINE; DIPHENHYDRAMINE; DOPAMINE; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; EUPHORIA; FEMALE; HOMOVANILLIC ACID; HUMANS; MALE; METHOXYHYDROXYPHENYLGLYCOL; METHYLTYROSINES; MIDDLE AGED; NOREPINEPHRINE; PROLACTIN; SUBSTANCE-RELATED DISORDERS;

EID: 0030878069     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(96)00331-9     Document Type: Article

References (54)

1. Aronson SC, Black JE, McDougle CJ, et al (1995): Serotonergic mechanisms of cocaine effects in humans. Psychopharmacology 119:179-185.
2. Bacopoulos NH, Hattox SE, Roth RH (1979) 3,4-Dihydroxyphenylacetic acid and homovanillic acid in rat plasma: possible indicators of central dopaminergic activity. Eur J Pharmacol 56:225-236.
3. Barrett RL, Appel JB (1989): Effects of stimulation and blockage of dopamine receptor subtypes on the discriminative stimulus properties of cocaine. Psychopharmacology 99:13-16.
4. Beck AT (1967): Depression: Clinical, Experimental and Theoretical Aspects. New York: Harper & Row.
5. Beitner-Johnson D, Nestler EJ (1992): Basic neurobiology of cocaine: Actions within the mesolimbic dopamine system. In Kosten TR, Kleber HB (eds), Clinician's Guide to Cocaine Abuse. New York: Guilford Press, pp 55-87.
6. Berger P, Gawin F, Kosten TR (1989): Treatment of cocaine abuse with mazindol. Lancet i:283.
7. Bunney WE, Brodie HK, Murphy DL, Goodwin FK (1971): Studies of alpha-methyl-para-tyrosine in depression and mania. Am J Psychiatry 127:872-881.
8. Byck T, Rusking D, Ungerer J, Jatlow PI (1982): Naloxone potentiates cocaine in humans. Psychopharmacol Bull 18:214-215.
9. Caine SB, Koob GF (1993): Modulation of cocaine self-administration in the rat through D-3 dopamine receptors. Science 260:1814-1816.
10. Carlsson A, Rosengren E, Bertler A, Nilsson J (1957): Effects of reserpine on the metabolism of catecholamines. In Garattini S, Ghetti V (eds), Psychotropic Drugs. Amsterdam: Elsevier pp 57-64.
11. Dekirmenjian H, Maas JW (1974): MHPG in plasma. Clin Chem Acta 52:203-208.
12. de Wit H, Wise RA (1977): Blockage of cocaine reinforcement in rats with the dopamine receptor pimozide, but not with the noradrenergic blockers phentolamine or phenozbenzamine. Can J Psychol 31:195-203.
13. Dworkin SI, Smith JE (1986): Neurobiological aspects of drug seeking behavior. In Dews PB, Thompson T, Barrett JE (eds), Neurobehavioral Pharmacology, vol 6. Hillsdale, NJ: Lawrence Erlbaum, p 43.
14. Engelman K, Horwitz D, Jequier E, Sjoerdsma A (1968): Biochemical and pharmacologic effects of alpha-methylpara-tyrosine in a man. J Clin Invest 47:577-594.
15. Fischman MW, Schuster CR, Javaid J, Hatano Y, Davis J (1985): Acute tolerance development to the cardiovascular and subjective effects of cocaine. J Pharmacol Exp Ther 235:677-682.
16. Fischman MW, Foltin RW, Brady JV (1988): Human Drug Taking under Controlled Laboratory Conditions. NIDA Research Monograph Series 84:196-210.
17. Fischman MW, Foltin RW, Nestadt G, Pearlson GD (1990): Effects of desipramine maintenance on cocaine self-administration in humans. J Pharmacol Exp Ther 253:760-770.
18. Gawin FH (1986): Neuroleptic reduction of cocaine induced paranoia but not euphoria? Psychopharmacology 90:142-143.
19. Gawin FH, Kleber HD, Byck R, et al (1989): Desipramine facilitation of initial cocaine abstinence. Arch Gen Psychiatry 46:117-121.
20. Hamilton M (1959): The assessment of anxiety states by rating. Br J Med Psychol 32:50-52.
21. Hamilton M (1960): A rating scale for depression. J Neurol Neurosurg Psychiatry 143:533.
22. Jatlow P, Nadim H (1990): Determination of cocaine concentration in plasma by high performance liquid chromatography. Clin Chem 36:1436-1439.
23. Jönssen LE, Anggard E, Gunne LM (1971): Blockage of intravenous amphetamine euphoria in man. Clin Pharmacol Ther 12:889-896.
24. Kleber HD, Kosten TR, Gaspari J, Topazian M (1985): Nontolerance to the opioid antagonism of naltrexone. Biol Psychiatry 20:66-72.
25. Kosten TR (1989): Pharmacotherapeutic interventions for cocaine abuse: Matching patients to treatments. JNerv Ment Dis 177:379-389.
26. Kosten TR, Rounsaville BJ, Kleber HD (1987): A 2.5 year follow-up of cocaine use among treated opioid addicts: Have our treatments helped? Arch Gen Psychiatry 44:281-284.
27. Kosten TR, Gawin FH, Silverman DG, et al (1992a): Intravenous cocaine challenges during desipramine maintenance. Neuropsychopharmacology 7:169-176.
28. Kosten TR, Morgan CM, Falcione J, Schottenfeld RS (1992b): Pharmacotherapy for cocaine-abusing methadone-maintained patients using amantadine or desipramine. Arch Gen Psychiatry 49:894-898.
29. Lakoski JM, Cunningham KA (1988): The interaction of cocaine with central serotonergic neuronal systems: Cellular electrophysiologic approaches. NIDA Research Monograph Series 88:78-91.
30. Lawson-Wendlin KL, Demarest KT, Moore KE (1981): Differential effects of (+) amphetamine, methylphenidate and amfonelic acid on catecholamine synthesis in selected regions of the rat brain. J Pharmacol 33:803-804.
31. Maas JW, Hattox SE, Roth RH (1976): The determination of a brain arteriovenous difference for 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG). Brain Res 118:167-174.
32. Margolin A, Kosten TR, Petrakis I (1991): Bupropion reduces cocaine abuse in methadone-maintained patients. Arch Gen Psychiatry 48:87.
33. McDougle CJ, Black JE, Malison RT, et al (1994): Noradrenergic dysregulation during discontinuation of cocaine use in addicts. Arch Gen Psychiatry 51:713-719.
34. McLellan A, Luborsky L, Moody G, O'Brien C (1980): An improved diagnostic evaluation instrument for substance abuse patients: The addiction severity scale index. J Nerv Ment Dis 168:26-33.
35. Meyer RE (1992): New pharmacotherapies for cocaine dependence. . .revisited. Arch Gen Psychiatry 49:900-904.
36. Petrakis IL, Webb E, Abi-Dargham A, Cooney N, Charney DS, Krystal J (1993): Serotonin contributions to cue-induced craving in alcoholics. Alcohol Clin Exp Res 17, #335:231 (abstract).
37. Petrakis IL, Stine SM, Krystal JH, Satel SL, Kosten TR, Namanworth SN, Charney DS (1995): AMPT effects on cue-induced craving for cocaine. American Journal on Addictions: In Press.
38. Pozuelo J (1976): Supression of craving and withdrawal in humans addicted to narcotics or amphetamines by administration of alpha-methyl-para-tyrosine (AMPT) and 5 butylpicolinic acid (fusaric acid). Cleve Clin Q 43:89-94.
39. Ritz MC, Lamd RJ, Goldberg SR, Kuhar MJ (1987): Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237:1219-1223.
40. Roberts DCS, Corcoran ME, Fibiger HC (1977): On the role of ascending catecholaminergic systems in intravenous self-administration of cocaine. Pharmacol Biochem Behav 6:615-620.
41. Satel SL, Krystal JH, Delgado PL, Kosten TR, Charney DS (1995): Tryptophan depletion and attenuation of cue-induced craving for cocaine. Am J Psychiatry 152:778-783.
42. Sherer MA, Kumor KM, Jaffe JH (1989): Effects of intravenous cocaine are partially attenuated by haloperidol. Psychiatry Res 27:117-125.
43. Shore PA (1971): Reserpine: A survey of its pharmacology. In Lajtha A (ed), Handbook of Neurochemistry. vol 5. p 349.
44. Shore PA, Brodie BB (1957): Influence of various drugs on serotonin and norepinephrine in the brain. In Garattini S, Ghetti V (eds), Psychotropic Drugs. Amsterdam: Elsevier pp 45-53.
45. Shore PA, Silver SL, Brodie BB (1955): Interaction of reserpine, serotonin, and lysergic acid diethylamide in brain. Science 122:284.
46. Singha AK, Appel JB (1992): The role of DA, NA, and 5-HT neuronal systems in the discriminative stimulus effects of cocaine. Soc Neurosci Abs 18.
47. Spealman RD (1990): Antagonism of behavioral effects of cocaine by selective dopamine receptor blockers. Psychopharmacology 101:142-145.
48. Task Force on Late Neurological Effects of Antipsychotic Drugs (1980): Tardive dyskinesia: Summary of a task force report of the American Psychiatric Association. Am J Psychiatry 137:1163-1172.
49. Wallach MB, Gershon S (1972): The induction and antagonism of central nervous system stimulant-induced stereotyped behavior in the cat. Eur J Pharmacol 18:22-26.
50. Weddington WW, Brown BS, Haertzen CA, et al (1991): Comparison of amantadine and desipramine combined with psychotherapy for treatment of cocaine dependence. Am J Drug Alcohol Abuse 17:137-152.
51. Willner JH, Samach M, Angrist BM, Wallach MB, Gershon S (1970): Drug induced stereotyped behavior and its antagonism in dogs. Commun Behav Biol 5:135-141.
52. Wilson MC, Schuster CR (1974): Aminergic influences on intravenous cocaine self-administration by rhesus monkeys. Pharmacol Biochem Behav 2:563-571.
53. Wise R (1984): Neural mechanisms of the reinforcing action of cocaine. National Institute of Drug Abuse Research Monograph Series 50:15-53.
54. Woolverton WL (1987): Evaluation of the role of norepinephrine in the reinforcing effects of psychomotor stimulants in rhesus monkeys. Pharmacol Biochem Behav 26:835-839.